Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA BerobenatideBusiness Wire • 06/06/26
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AIBusiness Wire • 06/04/26
Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/03/26
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026Zacks Investment Research • 06/02/26
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal CancerBusiness Wire • 05/31/26
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate CancerBusiness Wire • 05/30/26
Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung CancerBusiness Wire • 05/29/26
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology MedicinesPRNewsWire • 05/28/26
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology MedicinesBusiness Wire • 05/28/26
Insiders Aren't Buying Pfizer Stock at $26 and That's Actually a Good Thing24/7 Wall Street • 05/28/26